BD's Q2 Revenues Drop Slightly While Biosciences Biz Rises 3 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues were down less than 1 percent year over year, but its BD Biosciences segment managed three percent revenue growth for the quarter.

The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.74 billion for the three-month period ended March 31, down from revenues of $1.75 billion in the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.